Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals is viewed favorably because its portfolio is diversifying beyond Xyrem, with new products already driving about 65% of sales in 2022 and total sales estimated to rise from $2.4B in 2020 to $4.3B in 2026. Its neuroscience franchise should keep growing through Xywav and Epidiolex, while oncology can accelerate on Zepzelca, Rylaze, and especially Ziihera, whose 1L HER2+ GEA approval broadened its commercial reach and raised management’s peak revenue view to $3-5B from $2B+. The launch also looks de-risked by an ~8K annual U.S. HER2+ GEA incidence, a ~3-4K treatable population, existing J-codes and reimbursement, and manageable diarrhea with low discontinuation rates, supporting a durable growth thesis.

Jazz Pharmaceuticals is exposed to significant downside from concentrated revenue streams and heavy dependence on a few key products, making its outlook vulnerable if any of its franchise assets underperform. Regulatory and clinical risk is high because Phase 3 trials of Zepzelca may fail to show benefit in first-line SCLC, while early pipeline candidates such as JZP150 and JZP385 could produce negative readouts. Commercial and competitive pressure also weighs on fundamentals, as Rylaze and Epidiolex may grow more slowly than expected, generic Xyrem and once-nightly Lumryz could cap Xywav’s long-term share, and Epidiolex faces potential generic competition as early as after expiration of ODE in 2027.